Literature DB >> 12746732

Pharmacoproteomics in drug development.

Frank A Witzmann1, Raymond A Grant.   

Abstract

The field of proteomics is taking on increased significance as the relevance of investigating and understanding protein expression in disease and drug development is appreciated. Recent advances in proteomics have been driven by the availability of numerous annotated whole-genome sequences and a broad range of technological and bioinformatic developments that underscore the complexity of the proteome. This review briefly addresses some of the various technologies that comprise Expression Proteomics and Functional Proteomics, citing examples where these emerging approaches have been applied to pharmacology, toxicology, and the development of drugs.

Mesh：

Substances：

Year:  2003        PMID： 12746732     DOI： 10.1038/sj.tpj.6500164

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


  9 in total

Review 1.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

2.  Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism.

Authors:  Vivaswath S Ayyar; Richard R Almon; Debra C DuBois; Siddharth Sukumaran; Jun Qu; William J Jusko
Journal:  J Proteomics       Date:  2017-03-14       Impact factor: 4.044

3.  Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes.

Authors:  Valentina Calamia; Patricia Fernández-Puente; Jesús Mateos; Lucía Lourido; Beatriz Rocha; Eulália Montell; Josep Vergés; Cristina Ruiz-Romero; Francisco J Blanco
Journal:  Mol Cell Proteomics       Date:  2011-12-27       Impact factor: 5.911

Review 4.  Precision medicine: from pharmacogenomics to pharmacoproteomics.

Authors:  Allison B Chambliss; Daniel W Chan
Journal:  Clin Proteomics       Date:  2016-09-26       Impact factor: 3.988

Review 5.  Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Authors:  Daniel Gonzalez; Gauri G Rao; Stacy C Bailey; Kim L R Brouwer; Yanguang Cao; Daniel J Crona; Angela D M Kashuba; Craig R Lee; Kathryn Morbitzer; J Herbert Patterson; Tim Wiltshire; Jon Easter; Scott W Savage; J Robert Powell
Journal:  Clin Transl Sci       Date:  2017-08-10       Impact factor: 4.689

6.  Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage.

Authors:  Shijun He; Xing Liu; Zemin Lin; Yuting Liu; Lei Gu; Hu Zhou; Wei Tang; Jianping Zuo
Journal:  Arthritis Res Ther       Date:  2019-01-29       Impact factor: 5.156

Review 7.  New strategies in drug discovery.

Authors:  Eliot H Ohlstein; Anthony G Johnson; John D Elliott; Anne M Romanic
Journal:  Methods Mol Biol       Date:  2006

8.  Proteomic Analysis of Stage-II Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues.

Authors:  Naif Abdullah Al-Dhabi; Srisesharam Srigopalram; Soundharrajan Ilavenil; Young Ock Kim; Paul Agastian; Rajasekhar Baaru; Kannan Balamurugan; Ki Choon Choi; Mariadhas Valan Arasu
Journal:  Biomed Res Int       Date:  2016-03-24       Impact factor: 3.411

9.  ITRAQ-based quantitative proteomic analysis of processed Euphorbia lathyris L. for reducing the intestinal toxicity.

Authors:  Yu Zhang; Yingzi Wang; Shaojing Li; Xiuting Zhang; Wenhua Li; Shengxiu Luo; Zhenyang Sun; Ruijie Nie
Journal:  Proteome Sci       Date:  2018-04-17       Impact factor: 2.480
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.